Üstün OSMA, Ömer Tarık SELÇUK, Mete EYİGÖR, Levent RENDA, Nursel TÜRKOĞLU SELÇUK, Hülya EYİGÖR, Mustafa Deniz YILMAZ, Oğuzhan İLDEN, Ünal Gökalp IŞIK, Hande KONSUK ÜNLÜ, Meral GÜLTEKİN

Do serum copeptin levels change with positive airway pressure treatment in patients with severe obstructive sleep apnea?

Objectives: The aim of this study was to evaluate serum copeptin levels in patients with obstructive sleep apnea OSA before and after the positive airway pressure PAP treatment. Patients and Methods: A total of 16 patients 14 males, 2 females; median age 48 years; range, 38 to 60 years with severe sleep apnea based on the Apnea Hypopnea Index AHI >30 and 20 healthy controls 10 males, 10 females; median age 35.5 years; range, 22 to 47 years were included in this study between October 2014 and December 2015. Full-night polysomnography was applied to each patient. Serum copeptin levels were determined using the enzyme-linked immunosorbent assay in both groups. Serum copeptin level measurement was repeated in the patient group after one year of PAP treatment. Results: After one year of PAP treatment, serum copeptin levels of the patients with OSA decreased, although there was no statistically significant difference before and after treatment. Conclusion: Increased serum copeptin concentration may reflect a response to moderate stress in many diseases, particularly cardiovascular diseases. Based on our study results, there was no significant difference between the severe OSA group and healthy volunteers and before and after treatment among the patients with severe OSA.

Keywords:

Copeptin, severe obstructive sleep apnea, sleep apnea, vasopressin.,

PDF

___

Dyken ME, Im KB. Obstructive sleep apnea and stroke. Chest 2009;136:1668-77.
Tuomilehto H, Seppä J, Uusitupa M. Obesity and obstructive sleep apnea--clinical significance of weight loss Sleep Med Rev 2013;17:321-9.
Quercioli A, Mach F, Montecucco F. Inflammation accelerates atherosclerotic processes in obstructive sleep apnea syndrome (OSAS). Sleep Breath 2010;14:261-9.
Ozben S, Guvenc TS, Huseyinoglu N, Sanivar HS, Hanikoglu F, Cort A, et al. Low serum copeptin levels in patients with obstructive sleep apnea. Sleep Breath 2013;17:1187-92.
Yalta K, Yalta T, Sivri N, Yetkin E. Copeptin and cardiovascular disease: a review of a novel neurohormone. Int J Cardiol 2013;167:1750-9.
Katan M, Morgenthaler N, Widmer I, Puder JJ, König C, Müller B, et al. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett 2008;29:341-6.
Selcuk OT, Eyigor M, Renda L, Osma U, Eyigor H, Selcuk NT, et al. Can we use serum copeptin levels as a biomarker in obstructive sleep apnea syndrome? J Craniomaxillofac Surg 2015;43:879-82.
Çınarka H, Kayhan S, Karataş M, Yavuz A, Gümüş A, Özyurt S, et al. Copeptin: a new predictor for severe obstructive sleep apnea. Ther Clin Risk Manag 2015;11:589-94.
Izci B, Ardic S, Firat H, Sahin A, Altinors M, Karacan I. Reliability and validity studies of the Turkish version of the Epworth Sleepiness Scale. Sleep Breath 2008;12:161-8.
Berry RB, Budhiraja R, Gottlieb DJ, Gozal D, Iber C, Kapur VK, et al. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med 2012;8:597-619.
Kiely JL, McNicholas WT. Cardiovascular risk factors in patients with obstructive sleep apnoea syndrome. Eur Respir J 2000;16:128-33.
Yalta K, Sıvrı N, Yalta T, Geyik B, Aksoy Y, Yetkın E. Copeptin (C-terminal provasopressin): a promising marker of arrhythmogenesis in arrhythmia prone subjects? Int J Cardiol 2011;148:105.
Seligman R, Ramos-Lima LF, Oliveira Vdo A, Sanvicente C, Pacheco EF, Dalla Rosa K. Biomarkers in community-acquired pneumonia: a state-of-the-art review. Clinics (Sao Paulo) 2012;67:1321-5.
Itoi K, Jiang YQ, Iwasaki Y, Watson SJ. Regulatory mechanisms of corticotropin-releasing hormone and vasopressin gene expression in the hypothalamus. J Neuroendocrinol 2004;16:348-55.
Voors AA, von Haehling S, Anker SD, Hillege HL, Struck J, Hartmann O, et al. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J 2009;30:1187-94.
Katan M, Müller B, Christ-Crain M. Copeptin: a new and promising diagnostic and prognostic marker. Crit Care 2008;12:117.
Christ-Crain M, Müller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 2007;30:556-73.